Finanzas de Varex Imaging Corp (VREX)VREXVarex Imaging Corp

Varex Imaging Corporation (VREX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medical, accounting for 63.7% of total sales, equivalent to $134.00M. Another important revenue stream is Industrial. Understanding this composition is critical for investors evaluating how VREX navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Varex Imaging Corporation maintains a gross margin of 36.44%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.83%, while the net margin is 7.55%. These profitability ratios, combined with a Return on Equity (ROE) of 4.64%, provide a clear picture of how effectively VREX converts its operational activities into shareholder value.

In the context of the broader market, VREX competes directly with industry leaders such as MLAB and AVR. With a market capitalization of $779.74M, it holds a significant position in the sector. When comparing efficiency, VREX's gross margin of 36.44% stands against MLAB's 64.87% and AVR's 76.91%. Such benchmarking helps identify whether Varex Imaging Corporation is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of 36.44% in the latest quarter, indicating solid profitability potential, but it has also faced fluctuations in net income, with a recent net income of $15.7 million in Q3 2026 after previous losses.